TOPOTECAN-ORIGINAL-PHASE2

Regimen

Experimental
Topotecan 1.5 mg/m2 daily x5 q21d
Control
Cyclophosphamide 1000 mg/m2 + doxorubicin 45 mg/m2 + vincristine 2 mg (CAV), day 1 q21d

Population

SCLC patients who relapsed >=60 days after completion of first-line therapy (sensitive relapse), ECOG <=2

Key finding

ORR 24.3% (topotecan) vs 18.3% (CAV), P=0.285; mTTP 13.3 vs 12.3 wks (P=0.552); mOS 25.0 vs 24.7 wks (P=0.795); topotecan improved symptom control in 4/8 symptoms

Source: PMID 10080612

Timeline

    Guideline citations

    • NCCN SCLC (p.25)
    • CSCO SCLC 2025 (p.92)⚠️ OCR source